U.S. markets closed
  • S&P Futures

    4,198.50
    -24.50 (-0.58%)
     
  • Dow Futures

    33,837.00
    -180.00 (-0.53%)
     
  • Nasdaq Futures

    13,874.25
    -107.00 (-0.77%)
     
  • Russell 2000 Futures

    2,290.40
    -19.70 (-0.85%)
     
  • Crude Oil

    71.55
    -0.60 (-0.83%)
     
  • Gold

    1,817.80
    -43.60 (-2.34%)
     
  • Silver

    27.26
    -0.55 (-1.98%)
     
  • EUR/USD

    1.1995
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3981
    -0.0006 (-0.04%)
     
  • USD/JPY

    110.7650
    +0.1520 (+0.14%)
     
  • BTC-USD

    38,587.54
    -1,365.12 (-3.42%)
     
  • CMC Crypto 200

    956.83
    -35.64 (-3.59%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,010.74
    -280.27 (-0.96%)
     

Cannabis potency patent granted by USPTO

·2 min read

Panacea Plant Sciences patent holds key to creating higher levels of THC, CBD, CBG, THCV, terpenes and more in cannabis

BELLEVUE, Wash., Feb. 18, 2021 /PRNewswire/ -- Panacea Plant Sciences announced that its first patent application for methods to manipulate the yield and growth of cannabis (hemp) plants (US20180279611) has been granted by the USPTO. The award comes at a pivotal moment as the company has recently begun meetings with the Environmental Protection Agency (EPA) to seek new product approvals.

Panacea Plant Sciences is a leading biotechnology company focused on developing new cultivation, extraction and isolation techniques for cannabis, psychedelic plants and fungi, as well as therapies that derive from them.  Panacea is developing an extensive IP portfolio that includes trademarks, patents, university partnerships and products. Panacea's patent on increasing yields of cannabinoids and terpenes was granted by the USPTO several additional patents have been filed or are in progress.
Panacea Plant Sciences is a leading biotechnology company focused on developing new cultivation, extraction and isolation techniques for cannabis, psychedelic plants and fungi, as well as therapies that derive from them. Panacea is developing an extensive IP portfolio that includes trademarks, patents, university partnerships and products. Panacea's patent on increasing yields of cannabinoids and terpenes was granted by the USPTO several additional patents have been filed or are in progress.

"This award is a great foundation for the portfolio of IP we've developed," Panacea Plant Sciences CEO David Heldreth said. "We hope to achieve EPA approval for hemp by the end of 2021 and offer ways for farmers to create a superior crop."

The patent revolves around the use of phytohormone mixtures to induce higher and altered levels of cannabinoids and terpenes in the cannabis plant. Cannabinoids, such as THC and CBD, are famous as the active compounds in cannabis, but terpenes play a role in the combined therapeutic and recreational use through what is commonly called the entourage effect. Terpenes are also responsible for the flavor and taste of cannabis and other plants such as lavender (linalool) or pine trees (alpha-pinene).

Panacea Plant Sciences patent licensees will be able to increase the production of rare cannabinoids such as tetrahydrcannabivarin (THCV) which is currently in low supply and is valued at approximately $30,000 a kilo. The patent additionally applies to methods to reduce water use and increase fungi symbioses in the cannabis root system.

Panacea Plant Sciences has filed numerous other pending patents covering cannabis as well psychedelic (Peyote, Mescaline, DMT, Psilocybin, etc) cultivation and formulations.

About Panacea Plant Sciences
Panacea Plant Sciences is a leading biotechnology company at the forefront of developing new methods of agriculture for the cultivation of rare and valuable species of bacteria, fungi, and plants as well as ways to clothe, feed, heal and inspire humanity.

Media Contacts
Phone: (425) 728-0994
Info@panaceaplantsciences.net
www.Panaceaplantsciences.net

This press release contains 'forward-looking information' within the meaning of applicable securities legislation. These statements relate to future events or future performance. Forward-looking information in this press release includes information with respect to pending U.S. patent applications, and approval by the US EPA. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of publication.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabis-potency-patent-granted-by-uspto-301231151.html

SOURCE Panacea Plant Sciences